Moderna swings to profit as momentum for cancer vaccine builds

Moderna reported its first quarterly profit in two years, driven by momentum from its melanoma vaccine. The US biotech company's earnings reflect positive developments in its cancer vaccine program.

Original reporting

finance.yahoo.com

Published Nov 6, 2026, 11:45 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 6, 2026, 12:09 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · finance.yahoo.com

Decision brief

The 30-second read

$MRNABullishMed

Why it matters

The profit announcement could trigger short-covering and new buying, especially among biotech-focused funds.

Market read

Earnings surprise may move Moderna and influence biotech sentiment.

What to watch

Potential upcoming pipeline risks or R&D spending could offset profit gains.

Relevance 7/10Novelty 7/10Timing: today

Background

Moderna has been posting losses for the past two years; this profit marks a reversal.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MRNABullishHigh confidence

Context

Moderna reported its first quarterly profit in two years, a new earnings outcome for the company.

Expected impact

upward pressure as investors price in the profit turnaround

Evidence & confidence

First profit after a loss streak signals operational improvement and may trigger buying.

Market effects

Sector

Biotech sector may see modest uplift from a profit turnaround story.

Regional

U.S. markets could see a small boost in biotech indices.

Global

Limited to investors tracking biotech earnings.

Counterpoint

What could challenge this read

Profit may be one-time and not sustainable; caution on overbuying.

Key entities

company
Moderna
U.S. biotech firm developing mRNA therapeutics.

Read at source ← All news

$MRNAHighAI 8/10

Moderna, Inc. Q3 2026 Earnings Call Summary

Moderna reported 29% revenue growth and $200M net income in Q3 2026, driven by mNEXSPIKE adoption and cost reductions. The company raised its full-year revenue guidance to 15-25% and plans to submit a BLA for Intismeran in melanoma by year-end. It also secured $3B for oncology growth and paused a norovirus vaccine program. Management expressed confidence in upcoming clinical milestones and proprietary cancer therapy advantages.

finance.yahoo.comNov 6

$GSKLow

GSK, Moderna settle patent dispute over Moderna COVID, RSV shots

GSK and Moderna settled patent disputes over Moderna's COVID-19 and RSV vaccines, granting cross-licenses with no financial obligations. Both companies requested dismissal of GSK's US claims. GSK had previously sued Moderna and separately sued Pfizer and BioNTech over similar technology.

finance.yahoo.comNov 6

$MRNAHighAI 9/10

Moderna swung to profit and raised its revenue outlook in Q3 earnings

Moderna reported Q3 profit of $0.38 per share, up from a loss of $0.51 last year, with revenue rising 29% to $1.3B. The company raised its full-year revenue growth outlook to 15%-25%. Analysts expected a loss of $1.25 per share and revenue of $885.1M. Stock rose 3% in premarket trading.

qz.comNov 6

$MRNAHighAI 8/10

Moderna earnings analysis: questions answered and next catalysts

Moderna Inc (MRNA) reported Q3 2026 earnings with a profit swing, revenue up 29% YoY to $1.31B, and net income of $162M. Guidance raised, cash position improved, and FDA approved flu vaccine. Stock up 765% YTD, trading at $256.94. Analysts divided on valuation and durability of earnings.

investing.comNov 6

$MRNAHighAI 9/10

Why is Moderna stock rising nearly 9% today?

Moderna (MRNA) reported a $162M Q3 profit, beating estimates, and raised its full-year revenue growth forecast to 15%-25%. Covid vaccine sales drove revenue up 29% YoY to $1.31B. Shares surged 9% on the news, reflecting investor interest in its cancer vaccine and mRNA pipeline.

invezz.comNov 6

$IONQMedAI 8/10

Stocks making the biggest moves midday: Nvidia, Moderna, IonQ, Airbnb, Firefly Aerospace & more

IonQ rose 17% after raising revenue guidance to $505M-$515M. Firefly Aerospace surged 30% on a $1.3B deal with AST SpaceMobile. Microchip Technology fell 14% due to weak guidance. Moderna gained 7% after beating earnings and raising sales outlook. Lam Research jumped 9% on a $25B buyback plan. Five9 dropped 17% after lowering EPS guidance and announcing an acquisition. Airbnb climbed 11% on strong earnings. JFrog soared 35% after raising full-year guidance.

cnbc.comNov 6